MLH1 is altered in 2.3% of endometrial clear cell adenocarcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for endometrial clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and endometrial clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is altered in 8.14% of endometrial clear cell adenocarcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for endometrial clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and endometrial clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 3.49% of endometrial clear cell adenocarcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for endometrial clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and endometrial clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 1.27% of endometrial clear cell adenocarcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for endometrial clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and endometrial clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].